Next report date
Report period
Q1 2024
EPS estimate
0.64EUR
Revenue estimate
185.12 MEUR
1.94EUR
255.13 MEUR
751.31 MEUR
125.74 M
About Halozyme Therapeutics, Inc.
Sector
Industry
CEO
Helen I. Torley
Website
Headquarters
San Diego
Employees (FY)
373
Founded
1998
FIGI
BBG000FPXY33
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where RV7 is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange HALOZYME THERAPEU.DL-,001 stocks are traded under the ticker RV7.
HALOZYME THERAPEU.DL-,001 is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
RV7 earnings for the last quarter are 0.71 EUR per share, whereas the estimation was 0.67 EUR resulting in a 6.21% surprise. The estimated earnings for the next quarter are 0.72 EUR per share. See more details about HALOZYME THERAPEU.DL-,001 earnings.
HALOZYME THERAPEU.DL-,001 revenue for the last quarter amounts to 204.37 M EUR despite the estimated figure of 204.41 M EUR. In the next quarter revenue is expected to reach 209.29 M EUR.
Yes, you can track HALOZYME THERAPEU.DL-,001 financials in yearly and quarterly reports right on TradingView.
RV7 net income for the last quarter is 77.36 M EUR, while the quarter before that showed 77.42 M EUR of net income which accounts for −0.07% change. Track more HALOZYME THERAPEU.DL-,001 financial stats to get the full picture.
No, RV7 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RV7 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HALOZYME THERAPEU.DL-,001 stock right from TradingView charts — choose your broker and connect to your account.
As of May 2, 2024, the company has 373.00 employees. See our rating of the largest employees — is HALOZYME THERAPEU.DL-,001 on this list?
We've gathered analysts' opinions on HALOZYME THERAPEU.DL-,001 future price: according to them, RV7 price has a max estimate of 67.59 EUR and a min estimate of 36.61 EUR. Read a more detailed HALOZYME THERAPEU.DL-,001 forecast: see what analysts think of HALOZYME THERAPEU.DL-,001 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HALOZYME THERAPEU.DL-,001 EBITDA is 382.70 M EUR, and current EBITDA margin is 50.94%. See more stats in HALOZYME THERAPEU.DL-,001 financial statements.